What Стиламин Treats: Main Uses and Benefits

Стиламин (Stilamine) generally provides supportive therapeutic benefit in clinical settings that involve acute or unstable symptom patterns associated with certain serious conditions. This medication is commonly used to help with symptoms linked to organ-specific functional stress in conditions presenting with acute episodes, including bleeding from esophageal varices and other acute upper gastrointestinal hemorrhage events. It is also applied when short-term symptomatic assistance is needed in managing complex pancreatic dysfunction, such as acute pancreatitis, and certain post-surgical complications like fistulae.

Its use may assist with maintaining functional stability and contributes to easing the overall symptom load during difficult episodes. The medication is relevant when supportive symptom management is appropriate in situations where symptoms create noticeable functional strain.

---

Quick Fact: Relief for Symptoms associated with acute or episodic changes

---

Official Regulatory Eligibility for Стиламин (Somatostatin)

Official labeling defines who is permitted, restricted, or prohibited from using the Somatostatin injection (Стиламин) based strictly on governmental regulatory criteria.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with known hypersensitivity (allergy) to the active substance or to any of the preparation's excipients.
Populations for whom use is not recommended	Pediatric patients (children and adolescents), as safety and effectiveness have not been established in this age group.
Pregnancy and lactation eligibility status	Use is not recommended during pregnancy or lactation due to limited data on human risk and potential effects on the infant.
Eligibility-related restrictions	Cardiovascular Risk: Patients with pre-existing risk for cardiac conduction abnormalities (e.g., severe bradycardia) require caution and close monitoring during intravenous administration.
Condition-specific eligibility rules	Hepatic Impairment: Use with caution is required in patients with liver cirrhosis. Renal Impairment: No dose adjustment is typically required for the short-acting form.

Connection to the overall eligibility profile: Regulatory documents establish eligibility by setting an absolute contraindication for hypersensitivity and applying a not recommended status to vulnerable life stages, including pediatrics and reproductive phases, due to a lack of established data. Conditional use is required for the general adult population when specific cardiac or severe hepatic comorbidities are present, as detailed in regulatory warnings.

Interactions with other medicines and products

Стиламин (Somatostatin) has documented interaction patterns that primarily involve its potent pharmacodynamic effects and its influence on the systemic clearance of co-administered medicines. The regulatory profile emphasizes both formally contraindicated combinations and strict administration constraints based on physical and hormonal effects.

---

Prohibited Combinations and Constraints

The co-administration of Hexobarbital or Pentetrazol is formally prohibited due to the risk of potentiation of their central nervous system effects, as noted in official prescribing information. Additionally, the simultaneous administration of insulin-requiring sugars or glucose solutions should be avoided due to the medicine's immediate impact on glucose regulation.

Pharmacodynamic and Metabolic Effects

Due to its inhibitory effect on insulin and glucagon, use with antidiabetic drugs (insulin and oral hypoglycemics) requires monitoring and potential dosage adjustment to manage the risk of hyperglycemia or hypoglycemia. An additive effect on heart rate reduction (bradycardia) may occur with bradycardia-inducing drugs (e.g., Beta-blockers). Furthermore, the medicine may decrease the metabolic clearance of compounds metabolized by Cytochrome P450 (CYP) enzymes.

Exposure Changes and Timing Rules

Co-administration may lead to decreased bioavailability of substances like Cyclosporine and decreased exposure of Digoxin. Procedurally, a mandatory wash-out period of 2 days is required before certain somatostatin receptor-targeting radiopharmaceuticals for accurate diagnostic imaging. The medicine must be administered alone in the syringe and infusion solutions due to documented physical incompatibilities.

Somatostatin Receptor Binding and Signaling

Stilamin, a synthetic somatostatin analog, engages specific G-protein-coupled somatostatin receptors (SSTRs) across various physiological systems. Binding to all five SSTR subtypes (SSTR1–5) acts through the Gi protein to inhibit adenylyl cyclase. This action mediates a decrease in intracellular cyclic AMP ( cAMP) and modulates the flow of calcium ( Ca^2+) ions. This molecular cascade suppresses target cell secretory functions.

---

Modulating Gastrointestinal and Pancreatic Secretion

The drug modifies key pathways associated with the release of numerous gastrointestinal and pancreatic hormones and enzymes. It affects systems where mediators like gastrin, secretin, and cholecystokinin ( CCK) dominate. This inhibition regulates exocrine and endocrine processes at the cellular level, resulting in precise adjustments of targeted physiological activity.

---

Regulating Splanchnic Blood Flow

Stilamin engages mechanisms that induce regional vasoconstriction within the splanchnic circulation, which supplies the abdominal viscera. This vascular effect is a system-level consequence that modifies vessel tone and blood flow dynamics, resulting in a measurable decrease in blood flow velocity within the portal system.

How to use Стиламин

Administration of Стиламин (Somatostatin) is performed exclusively via the intravenous (IV) route and is reserved for settings where specialized monitoring can be ensured. The established method involves a specific two-part regimen for initiation and maintenance.

The first step requires an initial loading dose of 250 µg of Somatostatin, delivered as a slow IV injection over a period of 3 to 5 minutes. This is immediately followed by the primary therapeutic measure: continuous IV infusion at a standardized maintenance rate. The infusion rate is set at 250 µg/hour for all approved uses.

The medicine is supplied as a lyophilized powder and requires reconstitution with physiological sodium chloride solution immediately before administration. The resulting solution must be diluted further using compatible fluids, such as saline or 5% dextrose, and should be administered alone. Precise equipment, like a perfusion syringe, is recommended to ensure the accurate hourly flow rate is maintained.

Key Use Protocol	Guideline
Duration of Use	Typically, a maximum of 5 days for acute indications. Treatment for fistulae may last longer, up to 20 days.
Discontinuation	The infusion must be stopped progressively (tapered) after treatment for certain conditions to avoid a physiological rebound effect.
Missed Timing	If the continuous infusion is interrupted for more than 5 minutes, the 250 µg loading dose must be re-administered before restarting the maintenance infusion.

Dosing rules for children and adolescents have not been established.

Research Evidence / Overview of Studies for Стиламин

This overview describes what has been studied about the medicine Стиламин (Somatostatin) in formal clinical trials, focusing only on the structure of the research and the findings reported by scientists, without offering any clinical advice.

---

Evidence for Use in Acute Upper Gastrointestinal Hemorrhage

Research exploring the use of Somatostatin in this acute setting consists mainly of short-term randomized controlled trials (RCTs) and systematic reviews that combine the findings from multiple trials. These studies were applied in research contexts involving fluctuating or unstable symptoms related to significant internal bleeding in the upper digestive tract. The outcomes monitored in these trials included systemic or functional imbalance indicators, such as measurements of initial hemostasis, measurements related to active bleeding, the frequency of re-bleeding events after treatment started, and the blood transfusion requirements of the observed populations. Researchers also tracked overall mortality rates.

Studies examined measurements of initial hemostasis and reported on blood transfusion requirements across several cohorts. Findings were mixed or varied across studies, especially when evaluating patterns observed in major outcomes like overall 30-day mortality. Research has explored whether the medicine was associated with short-term symptom changes, but the observed patterns regarding survival were not uniformly consistent across all cohorts examined.

---

Evidence for Use in Complex Pancreatic Conditions

Somatostatin was evaluated in studies for patients with acute pancreatitis, which is a condition involving periods of heightened symptoms and outcomes linked to inflammatory or irritative states in the pancreas. Furthermore, research examined the use of the medicine for the prevention of post-surgical complications, specifically focusing on the incidence of a leak (pancreatic fistula) following complex surgery.

Studies reported varying measurements of complication rates in patients with acute pancreatitis, and other trials reported measurements of the incidence of pancreatic fistula formation in the post-operative population. Data show patterns related to the post-surgical use, where patterns in complication rates appeared more consistent than the findings for treating acute pancreatitis itself. Research explored whether monotherapy (Somatostatin alone) was associated with improvements in clinical outcomes like mortality for acute pancreatitis, but findings were mixed and not consistently confirmed by systematic reviews.

---

Areas of Uncertainty and Gaps in the Evidence

The major uncertainty lies in the inconsistent findings observed when studies attempted to measure an effect on overall mortality, especially for acute gastrointestinal hemorrhage. Follow-up durations were limited to the short-term acute phase, which means research provides context but does not offer predictions about long-term consequences. Additionally, much of the relevant research explores synthetic Somatostatin analogues (similar, but not identical drugs) rather than the native molecule (Стиламин), meaning comparative evidence is lacking to fully establish the equivalence of findings.

Common questions about Стиламин (FAQ)

---

Q: Is Стиламин the same kind of medicine as [similar drug name]? What's the general difference?

A: Official information describes the active substance, Somatostatin, as a natural hormone found in the body. It is classified as a Growth Hormone Release Inhibitor. The drug preparation used is structurally identical to this natural peptide, distinguishing it from related synthetic drugs, known as somatostatin analogues (SSAs), which are often used for similar purposes.

Q: How quickly does Стиламин usually start to have an effect?

A: The official product information indicates that the drug has an extremely fast action. The naturally occurring hormone has a very short half-life, typically only 1 to 3 minutes, which refers to the time it takes for half of the drug to be eliminated from the bloodstream. The administration as a continuous intravenous infusion is intended to ensure immediate and consistent systemic exposure.

Q: Is it normal to feel a certain way when first starting Стиламин?

A: Clinical studies documented in official regulatory documents report several common adverse reactions. These include symptoms such as headache, abdominal pain, and fatigue. These events are reported in clinical studies at a frequency of 5% or greater.

Q: Are the reported side effects of Стиламин usually mild?

A: Official labeling categorizes adverse reactions based on their frequency and separates them into common versus serious events. While reactions like headache and fatigue are common, the drug’s safety profile also includes descriptions of serious adverse reactions, such as thromboembolic events (blood clots). This separation indicates a distinction in the potential severity of effects.

Q: How does the purpose of Стиламин compare to other common treatments in its class?

A: Regulatory information classifies this drug as the natural hormone/peptide. Its purpose is to act as an inhibitory regulator for various systems, particularly the gastrointestinal tract. This action is similar to what is achieved by synthetic somatostatin analogues (SSAs), which are other common treatments used for similar endocrine and gastrointestinal conditions.

Q: Is Стиламин considered a high-risk medication by regulatory bodies?

A: The medicine is classified as prescription-only and is reserved for use in specialized settings. Regulatory labeling includes both warnings about serious events, such as thromboembolic events, and formal contraindications for patients with existing blood clot conditions. These statements indicate the medicine is associated with risks that require close medical supervision.

Q: Are there any common tests or monitoring required while taking Стиламин?

A: Official prescribing information indicates that due to the drug’s impact on the regulation of insulin and glucagon, monitoring of blood glucose levels is recommended. Furthermore, if the patient develops any visual or ocular symptoms while using the medicine, official guidelines indicate an immediate discontinuation and a full ophthalmic evaluation is necessary.

Q: How long after stopping treatment might the effects of Стиламин last?

A: Official pharmacokinetics data shows that the natural hormone has an extremely short half-life, meaning it is quickly processed by the body. Consequently, the direct, immediate effects of the drug cease rapidly once the continuous infusion is stopped.

Q: Is there any data on how often people experience the serious side effects of Стиламин?

A: Regulatory documents provide data on the frequency of common adverse reactions, such as headache or fatigue, often listing a percentage like 5% or greater. However, the specific incidence rate for rare but serious adverse reactions, such as thromboembolic events, is not always quantified with a numerical percentage in the general adverse reaction tables.

Q: What does 'contraindicated' mean in the context of who can't take Стиламин?

A: According to official regulatory information, a contraindication is a medical situation in which a drug must absolutely not be used. It means that for individuals with certain pre-existing conditions, such as active thromboembolic disease or known hypersensitivity, the risk of using the medicine is considered unacceptable.

Q: Why does the official leaflet for Стиламин mention [specific inactive ingredient]?

A: Official documents list all components of a medicine, including inactive ingredients (also called excipients). This is primarily done so that patients and healthcare providers can identify any known allergies to these components, which would require the medicine to be contraindicated due to the risk of severe hypersensitivity reactions.

Q: If I feel better, is it necessary to complete the full course of Стиламин as described?

A: Official administration instructions state that the infusion should be stopped progressively, meaning it should be slowly tapered. This measure is required to help the body readjust and avoid a potential physiological rebound effect that can occur if the medicine is discontinued suddenly.

Q: How long does the drug stay in the system after the last dose, factually?

A: Regulatory pharmacokinetics data states that the elimination half-life for Somatostatin is extremely short, lasting only 1 to 3 minutes. The elimination half-life refers to the time it takes for the concentration of the drug in the blood to be reduced by half. This indicates it is cleared from the system very quickly.

Q: What is the difference between a side effect and an adverse event for Стиламин?

A: Regulatory documents use the term 'adverse reaction' to describe unintended negative effects that are reported during drug use. This term encompasses the patient experience of 'side effects' and 'adverse events,' all of which describe reactions linked to the medicine. Official reporting focuses on tracking these adverse reactions and classifying them by severity and frequency.

Q: What level of efficacy is generally noted in the pivotal trials for Стиламин?

A: Studies summarized in the official literature report varying findings depending on the condition being studied. For some major outcomes, such as overall mortality in acute gastrointestinal bleeding, results were mixed across studies. For post-surgical complications, like the prevention of a pancreatic fistula, research findings on complication rates were reported as more consistent.

The official requirements for the storage and disposal of Stilamin (somatostatin) are defined by specific regulatory constraints to maintain product stability.

Required Storage Conditions

Requirement	Official Statement
Temperature	Store the unopened powder below 25 C; Do not refrigerate or freeze the ampoules.
Protection	Keep the product in the original package to ensure protection from light.
Stability (Reconstituted)	The solution prepared for infusion is stable for 24 hours at 25 C.

The product must be stored out of the sight and reach of children.

Disposal Instructions

Official labeling requires that any unused or expired Stilamin must be disposed of according to local regulatory requirements. This mandates following established pharmaceutical waste procedures, often requiring return to a pharmacy or collection program, and generally prohibits disposal in household waste or wastewater.